Cargando…

Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report

BACKGROUND: Chronic heart failure (CHF) is a growing epidemic. The cornerstone of pharmacological therapy in CHF patients with reduced ejection fraction (HFrEF) is the inhibition of the renin–angiotensin–aldosterone system (RAAS). One of the adverse effects of RAAS blockade is the development of hyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez-Marrero, Santiago, Enjuanes, Cristina, Yun, Sergi, Comín-Colet, Josep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501904/
https://www.ncbi.nlm.nih.gov/pubmed/32974448
http://dx.doi.org/10.1093/ehjcr/ytaa103
_version_ 1783584123815723008
author Jiménez-Marrero, Santiago
Enjuanes, Cristina
Yun, Sergi
Comín-Colet, Josep
author_facet Jiménez-Marrero, Santiago
Enjuanes, Cristina
Yun, Sergi
Comín-Colet, Josep
author_sort Jiménez-Marrero, Santiago
collection PubMed
description BACKGROUND: Chronic heart failure (CHF) is a growing epidemic. The cornerstone of pharmacological therapy in CHF patients with reduced ejection fraction (HFrEF) is the inhibition of the renin–angiotensin–aldosterone system (RAAS). One of the adverse effects of RAAS blockade is the development of hyperkalaemia, which often limits the optimization of recommended, Class I treatments. In this context, potassium binders patiromer or sodium zirconium cyclosilicate (ZS-9) provide an opportunity to optimize the pharmacological management of these patients. CASE SUMMARY: We present a case report illustrating our real-life experience using the potassium-binder patiromer in a patient with HFrEF, in whom recurrent hyperkalaemia (up to 6.3 mmol/L with low doses of enalapril) was preventing titration of RAAS inhibition therapies. Use of patiromer allowed re-introducing ramipril (subsequently switched to sacubitril/valsartan) and eplerenone. Serum potassium levels remained normal with patiromer 16.8 g/24 h, and the patient’s tolerance to patiromer was excellent. DISCUSSION: In patients with HFrEF and recurrent hyperkalaemia, optimal RAAS inhibition is often discontinued. In this context, novel potassium binders such as patiromer or ZS-9 have been shown to be effective in lowering potassium and maintaining normokalaemia, with a good safety profile and patient tolerance, all of which make them promising alternative options. Our preliminary experience suggests that patiromer may be a helpful and well-tolerated treatment option, which may aid in achieving optimal RAAS inhibition in HFrEF patients with recurrent hyperkalaemia. Registries of HFrEF patients will help better understand whether therapies such as patiromer have prognostic benefits through facilitating optimal RAAS blockade.
format Online
Article
Text
id pubmed-7501904
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-75019042020-09-23 Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report Jiménez-Marrero, Santiago Enjuanes, Cristina Yun, Sergi Comín-Colet, Josep Eur Heart J Case Rep Case Reports BACKGROUND: Chronic heart failure (CHF) is a growing epidemic. The cornerstone of pharmacological therapy in CHF patients with reduced ejection fraction (HFrEF) is the inhibition of the renin–angiotensin–aldosterone system (RAAS). One of the adverse effects of RAAS blockade is the development of hyperkalaemia, which often limits the optimization of recommended, Class I treatments. In this context, potassium binders patiromer or sodium zirconium cyclosilicate (ZS-9) provide an opportunity to optimize the pharmacological management of these patients. CASE SUMMARY: We present a case report illustrating our real-life experience using the potassium-binder patiromer in a patient with HFrEF, in whom recurrent hyperkalaemia (up to 6.3 mmol/L with low doses of enalapril) was preventing titration of RAAS inhibition therapies. Use of patiromer allowed re-introducing ramipril (subsequently switched to sacubitril/valsartan) and eplerenone. Serum potassium levels remained normal with patiromer 16.8 g/24 h, and the patient’s tolerance to patiromer was excellent. DISCUSSION: In patients with HFrEF and recurrent hyperkalaemia, optimal RAAS inhibition is often discontinued. In this context, novel potassium binders such as patiromer or ZS-9 have been shown to be effective in lowering potassium and maintaining normokalaemia, with a good safety profile and patient tolerance, all of which make them promising alternative options. Our preliminary experience suggests that patiromer may be a helpful and well-tolerated treatment option, which may aid in achieving optimal RAAS inhibition in HFrEF patients with recurrent hyperkalaemia. Registries of HFrEF patients will help better understand whether therapies such as patiromer have prognostic benefits through facilitating optimal RAAS blockade. Oxford University Press 2020-06-28 /pmc/articles/PMC7501904/ /pubmed/32974448 http://dx.doi.org/10.1093/ehjcr/ytaa103 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Case Reports
Jiménez-Marrero, Santiago
Enjuanes, Cristina
Yun, Sergi
Comín-Colet, Josep
Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report
title Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report
title_full Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report
title_fullStr Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report
title_full_unstemmed Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report
title_short Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report
title_sort use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501904/
https://www.ncbi.nlm.nih.gov/pubmed/32974448
http://dx.doi.org/10.1093/ehjcr/ytaa103
work_keys_str_mv AT jimenezmarrerosantiago useofpotassiumbinderpatiromerforuptitrationofreninangiotensinaldosteronesysteminhibitiontherapyinapatientwithchronicheartfailureandreducedejectionfractionfollowedinamultidisciplinaryintegratedchroniccaremanagementprogrammeacasereport
AT enjuanescristina useofpotassiumbinderpatiromerforuptitrationofreninangiotensinaldosteronesysteminhibitiontherapyinapatientwithchronicheartfailureandreducedejectionfractionfollowedinamultidisciplinaryintegratedchroniccaremanagementprogrammeacasereport
AT yunsergi useofpotassiumbinderpatiromerforuptitrationofreninangiotensinaldosteronesysteminhibitiontherapyinapatientwithchronicheartfailureandreducedejectionfractionfollowedinamultidisciplinaryintegratedchroniccaremanagementprogrammeacasereport
AT comincoletjosep useofpotassiumbinderpatiromerforuptitrationofreninangiotensinaldosteronesysteminhibitiontherapyinapatientwithchronicheartfailureandreducedejectionfractionfollowedinamultidisciplinaryintegratedchroniccaremanagementprogrammeacasereport